



The Past, Present and Future of Photodynamic Therapy for Cancers

Guest Editors:

Dr. Sabrina Oliveira

Department of Biology and of
Pharmaceutical Sciences,
Utrecht University, Utrecht, The
Netherlands

Dr. Dominic Robinson

Department of
Otorhinolaryngology & Head and
Neck Surgery, Center for Optical
Diagnostics and Therapy,
Erasmus Medical Center,
Rotterdam, The Netherlands

Dr. Girgis Obaid

Laboratory of Dr. Tayyaba Hasan,
Harvard Medical School,
Wellman Center for
Photomedicine, Massachusetts
General Hospital, Boston, MA,
USA

Deadline for manuscript
submissions:

closed (15 January 2020)

Message from the Guest Editors

Photodynamic therapy was introduced more than one hundred years ago as a method that needed three elements to create local toxicity: a photosensitizer, light, and oxygen. Many preclinical studies and clinical trials have been conducted showing the great potential of this local cancer therapy, which has also been described to lead to systemic effects through activation of the immune system. Those studies led to the regulatory approval of PDT as a cancer treatment. Nonetheless, it is generally accepted that this treatment modality is still underutilized in the clinic. The Special Issue aims to assemble significant contributions in the following categories:

1. Crucial *past* efforts made in this field;
2. Insights into the *present* applications of PDT in the clinic;
3. Current developments focused on improving PDT, such as but not limited to:
Macromolecular targeting of photosensitizers;
Nanoparticles as photosensitizers' delivery vehicles;
Light delivery and dosimetry;
Combination of PDT with other therapies;
Immunological component of PDT;
Alternatives for hypoxic tumors;
4. Perspectives on the *future* of PDT.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department,
University Hospital Strasbourg,
67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and
Critical Care Medicine, University
of Tokyo, Tokyo 113-8655, Japan

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's (JCM)* staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Contact Us

Journal of Clinical Medicine Editorial
Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jcm
jcm@mdpi.com
[X@JCM_MDPI](https://twitter.com/JCM_MDPI)